SCHEMBL2483114

SCHEMBL2483114

COc1cccc(Cc2nc(Nc3ccc(-n4ccnc4C)cc3)nc3c2CN(C(=O)O)CC3)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.40
ROCK2 O75116 1/20 0.39
PDGFRB P09619 2/20 0.38
STAT6 P42226 1/20 0.38
MAPT P10636 3/20 0.37
CYP3A4 P08684 3/20 0.37
CYP2D6 P10635 3/20 0.37
LMNA P02545 3/20 0.37
CYP2C9 P11712 3/20 0.37
USP2 O75604 2/20 0.37
CASP1 P29466 2/20 0.37
CASP7 P55210 2/20 0.37
TSHR P16473 1/20 0.37
HIF1A Q16665 1/20 0.37
MCHR1 Q99705 1/20 0.37
PORCN Q9H237 1/20 0.37
JAK2 O60674 1/20 0.37
PTK2 Q05397 1/20 0.37
FLT1 P17948 1/20 0.36
FLT4 P35916 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2451842 0.94 CREBBP (0.41) KDRROCK2PDGFRBSTAT6MAPT
SCHEMBL8905655 0.91 MAPT (0.49) KDRROCK2PDGFRBSTAT6MAPT
SCHEMBL2483361 0.90 ROCK2 (0.40) KDRROCK2PDGFRBCYP3A4CYP2D6
SCHEMBL2447174 0.89 ROCK2 (0.43) KDRROCK2MAPTCYP3A4CYP2D6
SCHEMBL2482423 0.88 MAPT (0.40) KDRROCK2STAT6MAPTCYP3A4
SCHEMBL2448058 0.86 GPBAR1 (0.37) KDRROCK2PDGFRBCYP3A4CYP2D6
SCHEMBL2451479 0.84 PSEN1 (0.43)
SCHEMBL2480448 0.83 ROCK2 (0.39) KDRROCK2STAT6CYP3A4CYP2D6
SCHEMBL2446003 0.83 HTR2A (0.40) KDRSTAT6CYP3A4CYP2D6LMNA
SCHEMBL2839484 0.82 MAPT (0.46) ROCK2MAPTCYP3A4CYP2D6PORCN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 US disclosed
EP-2367826-A1 MODULATORS OF AMYLOID BETA. AstraZeneca AB (SE) 2011-09-28 EP disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 US disclosed
WO-2010053438-A1 MODULATORS OF AMYLOID BETA. ASTRAZENECA AB (SE) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130495-A1 COMPOUNDS 563 BACE1, PSEN1, PSEN2 KDR 587/4885ROCK2 445/4885PDGFRB 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.